Measuring treatment response to adalimumab in hidradenitis suppurativa patients: An observational study

Australas J Dermatol. 2020 Aug;61(3):292-294. doi: 10.1111/ajd.13245. Epub 2020 Feb 17.

Authors

Yonatan Kok¹, Jenny Nicolopoulos¹, Anna Braue^{1

2}, Johannes S Kern^{1

2

3}, George Varigos^{1

2}, Con Dolianitis^{1

2}

Affiliations

¹ Department of Dermatology, The Royal Melbourne Hospital, Parkville, Victoria, Australia.
² Department of Medicine, The University of Melbourne, Parkville, Victoria, Australia.
³ Department of Dermatology, Faculty of Medicine, Medical Center, University of Freiburg, Freiburg, Germany.

PMID: 32065658
DOI: 10.1111/ajd.13245

No abstract available

Publication types

Letter
Observational Study

MeSH terms

Adalimumab / therapeutic use*
Adolescent
Adult
Anti-Inflammatory Agents / therapeutic use*
Child
Cohort Studies
Female
Hidradenitis Suppurativa / drug therapy*
Humans
Male
Middle Aged
Outcome Assessment, Health Care
Treatment Outcome
Young Adult

Substances

Anti-Inflammatory Agents
Adalimumab